The Company also announced that it is actively negotiating a supply agreement for GMP IVT template with a mRNA therapeutic developer. Separately, the Company reaffirmed its intention to complete ...

Q1 2025 Management View The company announced a strategic restructuring to focus on its LineaRx subsidiary, exiting the DNA Tagging and Security Products and Services segment. This move is expected to ...